Cipla Subsidiary InvaGen Clears USFDA Inspection with No Observations
Cipla announced that its wholly owned subsidiary, InvaGen Pharmaceuticals, successfully passed a routine US Food and Drug Administration (USFDA) inspection at its manufacturing facility in Hauppauge, Long Island, New York. The inspection, conducted from October 19 to October 22, 2026, concluded with zero Form 483 observations, indicating full compliance with regulatory standards.
Economic Times··Hauppauge




